Oxford Biomedica PLC Holdings in Company (1974O)
06 February 2021 - 12:22AM
UK Regulatory
TIDMOXB
RNS Number : 1974O
Oxford Biomedica PLC
05 February 2021
TR-1 annoucement of major holdings
Oxford, UK - 5 February 2021: Oxford Biomedica plc ("Oxford
Biomedica" or "the Group") (LSE: OXB), a leading gene and cell
therapy group, today announces that Vulpes Testudo/Lifesciences
Fund, has advised the Group that on 4 February 2021 it sold 970,000
ordinary shares of 50p each in the Group. The shares have been
acquired by a subsidiary of Vitruvian Investment Partnership III, a
fund managed by Vitruvian Partners LLP. Vitruvian Partners is a
leading global growth investment firm with EUR10bn AUM, and has
supported some of Europe's most successful high growth innovators.
They are highly respected with a long term focus and strong
interest in cell and gene therapy.
Martin Diggle from VulpesTestudo/Lifesceinces Fund said:
"Through the recent sale of a portion of our holding to Vitruvian
Partners LLP, Oxford Biomedica gains another well respected
long-term shareholder. We are excited about the future for the
Group, remain fully supportive of the business and continue to
retain a significant shareholding."
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and
to the FCA in Microsoft Word format if possible) (i)
1a. Identity of the issuer or the OXFORD BIOMEDICA PLC
underlying issuer of existing shares
to which voting rights are attached
(ii) :
--------------------------------------------
1b. Please indicate if the issuer is a non-UK issuer (please mark with
an "X" if appropriate)
Non-UK issuer
----
2. Reason for the notification (please mark the appropriate box or boxes
with an "X")
An acquisition or disposal of voting rights X
----
An acquisition or disposal of financial instruments
----
An event changing the breakdown of voting rights
----
Other (please specify)(iii) :
----
3. Details of person subject to the notification obligation (iv)
Name VULPES LIFE SCIENCES FUND
VULPES TESTUDO FUND
City and country of registered office CAYMAN ISLANDS
(if applicable)
4. Full name of shareholder(s) (if different from 3.) (v)
Name
--------------------------------------------
City and country of registered office
(if applicable)
--------------------------------------------
5. Date on which the threshold was 04/02/2021
crossed or reached (vi) :
--------------------------------------------
6. Date on which issuer notified (DD/MM/YYYY): 05/02/2021
--------------------------------------------
7. Total positions of person(s) subject to the notification obligation
% of voting % of voting rights Total of both Total number
rights attached through financial in % (8.A + of voting rights
to shares (total instruments 8.B) of issuer (vii)
of 8. A) (total of 8.B
1 + 8.B 2)
------------------ --------------------- -------------- --------------------
Resulting situation
on the date
on which threshold
was crossed
or reached 11.86% 0% 11.86% 9,768,615
------------------ --------------------- -------------- --------------------
Position of
previous notification
(if
applicable) - 0%
------------------ --------------------- -------------- --------------------
8. Notified details of the resulting situation on the date on which the
threshold was crossed or reached (viii)
A: Voting rights attached to shares
Class/type Number of voting rights (ix) % of voting rights
of
shares
ISIN code
(if possible)
Direct Indirect Direct Indirect
(Art 9 of Directive (Art 10 of Directive (Art 9 of Directive (Art 10 of Directive
2004/109/EC) 2004/109/EC) 2004/109/EC) (DTR5.1) 2004/109/EC)
(DTR5.1) (DTR5.2.1) (DTR5.2.1)
--------------------------
GB0006648157 9,768,615 11.86%
---------------------- -------------------------- ------------------------- ---------------------
SUBTOTAL
8. A 9,768,615 11.86%
-------------------------------------------------- ------------------------------------------------
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC
(DTR5.3.1.1 (a))
Type of financial Expiration Exercise/ Number of voting % of voting rights
instrument date Conversion Period rights that may
(x) (xi) be acquired if
the instrument
is
exercised/converted.
----------- ------------------------------ -------------------------------- ---------------------
SUBTOTAL 8. B 1
------------------------------ -------------------------------- ---------------------
B 2: Financial Instruments with similar economic effect according to
Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of Expiration Exercise/ Physical or Number of % of voting rights
financial date (x) Conversion cash voting rights
instrument Period (xi) settlement
(xii)
---------------- -------------------- -------------------- --------------------
SUBTOTAL 8.B.2
-------------------- --------------------
9. Information in relation to the person subject to the notification
obligation (please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled X
by any natural person or legal entity and does not control any other
undertaking(s) holding directly or indirectly an interest in the
(underlying) issuer(xiii)
Full chain of controlled undertakings through which the voting rights
and/or the
financial instruments are effectively held starting with the ultimate
controlling natural person or legal entity(xiv) (please add additional
rows as necessary)
Name (xv) % of voting rights % of voting rights Total of both if
if it equals or through financial it equals or is
is higher than the instruments if it higher than the
notifiable threshold equals or is higher notifiable threshold
than the notifiable
threshold
---------------------- --------------------- ------------------------
10. In case of proxy voting, please identify:
Name of the proxy holder
-----------------------------------------------
The number and % of voting rights
held
-----------------------------------------------
The date until which the voting rights
will be held
-----------------------------------------------
11. Additional information (xvi)
Place of completion London, UK
Date of completion 04 February 2021
-----------------
Contact name: Natalie Walter
Contact telephone
number: 01865 783000
---------------
-Ends-
Enquiries:
Oxford Biomedica plc
John Dawson, Chief Executive Officer T: +44 (0)1865 783 000
Stuart Paynter, Chief Financial Officer T: +44 (0)1865 783 000
Catherine Isted, Head of Corporate T: +44 (0)1865 954 161 / E: ir@oxb.com
Development & IR
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal T: +44 (0)20 3709 5700
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene
and cell therapy group focused on developing life changing
treatments for serious diseases. Oxford Biomedica and its
subsidiaries (the "Group") have built a sector leading lentiviral
vector delivery platform (LentiVector(R) ), which the Group
leverages to develop in vivo and ex vivo products both in-house and
with partners. The Group has created a valuable proprietary
portfolio of gene and cell therapy product candidates in the areas
of oncology, ophthalmology, CNS disorders, liver diseases and
respiratory disease. The Group has also entered into a number of
partnerships, including with Novartis, Bristol Myers Squibb,
Sanofi, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam
Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene
Therapy Consortium and Imperial Innovations, through which it has
long-term economic interests in other potential gene and cell
therapy products. Additionally the group has signed a 3 year master
supply and development agreement with AstraZeneca for large-scale
manufacturing of the adenoviral based COVID-19 vaccine candidate,
AZD1222. Oxford Biomedica is based across several locations in
Oxfordshire, UK and employs more than 580 people. Further
information is available at www.oxb.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
HOLEADASEAEFEFA
(END) Dow Jones Newswires
February 05, 2021 08:22 ET (13:22 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024